JCIA
EGRX

Jackson Creek Investment Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Jackson Creek Investment Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-25,164
Closed -$714K – 373
2023
Q1 		$714K Sell
25,164
-7
-0% -$208 0.3% 186
2022
Q4 		$736K Buy
+25,171
New +$800K 0.33% 182
2022
Q2 		– Sell
-22,573
Closed -$1.12M – 392
2022
Q1 		$1.12M Buy
+22,573
New +$1.08M 0.41% 96

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jackson Creek Investment Advisors's EGRX Position: Q2 2023 in Review

Jackson Creek Investment Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 25,164 shares — an estimated $714K sold.

Jackson Creek Investment Advisors first reported a position in EGRX in Q1 2022 and held it in 3 quarters. The position peaked at $1.12M in Q1 2022. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

  • Jackson Creek Investment Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Jackson Creek Investment Advisors sold 25,164 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $714K.
  • Jackson Creek Investment Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2022 and held it in 3 quarters.
  • Jackson Creek Investment Advisors's Eagle Pharmaceuticals, Inc. position peaked at $1.12M in Q1 2022.
  • 126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on Jackson Creek Investment Advisors's 13F filing for Q2 2023, filed 3 Aug 2023.